View Item 

Show simple item record

Inflammatory breast carcinoma (carcinoma erysipeloides): an easily overlooked diagnosis

dc.contributor.authorFinkel, L. J.en_US
dc.contributor.authorGriffiths, Christopher E. M.en_US
dc.date.accessioned2010-06-01T22:44:13Z
dc.date.available2010-06-01T22:44:13Z
dc.date.issued1993-09en_US
dc.identifier.citationFINKEL, L.J.; GRIFFITHS, C.E.M. (1993). "Inflammatory breast carcinoma (carcinoma erysipeloides): an easily overlooked diagnosis." British Journal of Dermatology 129(3): 324-326. <http://hdl.handle.net/2027.42/75705>en_US
dc.identifier.issn0007-0963en_US
dc.identifier.issn1365-2133en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/75705
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=8286233&dopt=citationen_US
dc.description.abstractA 70-year-old woman developed erythema and induration of the right chest wall, and swelling of her right arm. The provisional diagnosis was deep venous thrombosis and for cellulitis of the right arm. Skin biopsy showed a poorly differentiated adenocarcinoma within lymphatic vessels, and immunohistochemical staining revealed this to be of breast origin. Inflammatory carcinoma or carcinoma erysipeloides represents 1% of all cases of breast carcinoma. Our case illustrates the importance of considering this entity in the differential diagnosis of unilateral chest wall erythema and induration.en_US
dc.format.extent1187748 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights1993 British Association of Dermatologistsen_US
dc.titleInflammatory breast carcinoma (carcinoma erysipeloides): an easily overlooked diagnosisen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelDermatologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Dermatology, University of Michigan Medical Center, Ann Arbor, Michigan 48109-03144. U.S.A.en_US
dc.identifier.pmid8286233en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/75705/1/j.1365-2133.1993.tb11855.x.pdf
dc.identifier.doi10.1111/j.1365-2133.1993.tb11855.xen_US
dc.identifier.sourceBritish Journal of Dermatologyen_US
dc.identifier.citedreferenceLee BJ, Tiiniieiibaum NE. Inflammatory carcinoma of the breast. Surg Gynecol Obstet 1924; 59: 580 – 95.en_US
dc.identifier.citedreferenceTaylor GW, Metzer A. Inflammatory carcinoma' of the breast. J Am J Cancer 1938; 33: 33 – 49.en_US
dc.identifier.citedreferenceHaupt HM, Hood AF, Cohen MH. Inflammatory melanoma. J Am Acad Dermtol 1984; 10: 52 – 5.en_US
dc.identifier.citedreferenceIngram JT. Carcinoma erysipelatodes and carcinoma telangiectaticum. Arch Dermatol 1958; 77: 227 – 31.en_US
dc.identifier.citedreferenceEdelstein JM. Pancreatic carcinoma with unusual metastasis to the skin and subcutaneous tissue simulating cellulitis. N Eng J Med 1950; 242: 779 – 81.en_US
dc.identifier.citedreferenceSiegel JM. Inflammatory carcinoma of the breast. Arch Dermatol Syphilol 1952; 66: 710 – 16.en_US
dc.identifier.citedreferenceMazoujian G, Pinkus GS, Davis S, Haagensen DF Jr. Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features. Am J Pathol 1983; 110: 105 – 12.en_US
dc.identifier.citedreferenceMazoujian G, Bodian C, Haagensen DE Jr, Haagensen CD. Expression of GCDFP–15 in breast carcinomas. Cancer 1989; 63: 2156 – 61.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2133.1993.tb11855.x.pdf
Size:
1.132MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.